This regulatory milestone accelerates the development timeline for cesalatamig, also known as AI-081, as the company prepares to transition into Phase 3 registrational trials. The drug is currently under scrutiny in the global BiPAVE-001 study, which encompasses clinical sites across the United States and China. Dr. Yang Liu, CEO and Chief Scientific Officer of OncoC4, noted that the designation follows promising safety and efficacy markers observed during initial dose-escalation and expansion phases.

Cesalatamig distinguishes itself from existing bevacizumab-based inhibitors through a high-affinity profile for both PD-1 and VEGF. By utilizing advanced Fc-silencing modifications, the molecule aims to preserve PD-1 positive effector T cells within the tumor microenvironment. As the company expands its oncology pipeline, which also includes the SIGLEC-10 antibody ONC-841 and a CTLA-4 collaboration with BioNTech, the focus remains on addressing resistance in patients where traditional therapies have failed.